AstraZeneca
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Study to Investigate the Management of Hypertension and Efficacy of AZD2171 in Patients With Advanced Solid Tumours
- First Posted Date
- 2005-12-12
- Last Posted Date
- 2012-08-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 119
- Registration Number
- NCT00264004
- Locations
- 🇬🇧
Research Site, Surrey, United Kingdom
ARAMIS: Actions of tesaglitazaR on fAt Metabolism and Insulin Sensitivity
- Conditions
- Type 2 Diabetes
- First Posted Date
- 2005-12-12
- Last Posted Date
- 2008-03-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 105
- Registration Number
- NCT00263965
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2005-12-08
- Last Posted Date
- 2016-11-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 389
- Registration Number
- NCT00263276
- Locations
- 🇵🇷
Local Institution, San Juan, Puerto Rico
🇨🇦Local institution, Bathurst, New Brunswick, Canada
🇺🇸Local Insitution, Edina, Minnesota, United States
C-Reactive Protein (CRP) in Obese Diabetic Women
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2005-12-07
- Last Posted Date
- 2007-08-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT00262548
- Locations
- 🇲🇽
Research site, Cuernavaca, Morelos, Mexico
Dose Response Study in Japanese Patients
- Conditions
- Type 2 Diabetes
- First Posted Date
- 2005-12-05
- Last Posted Date
- 2009-04-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 250
- Registration Number
- NCT00261417
- Locations
- 🇯🇵
Research Site, Takamori, Japan
Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416)
- Conditions
- Hay FeverPerennial Allergic Rhinitis
- First Posted Date
- 2005-12-05
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 102
- Registration Number
- NCT00261287
- Locations
- 🇺🇸
Altana Pharma/Nycomed, San Antonio, Texas, United States
GALLANT 14 Tesaglitazar vs. Metformin and Fenofibrate
- Conditions
- Type 2 Diabetes
- First Posted Date
- 2005-12-05
- Last Posted Date
- 2009-04-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT00261352
- Locations
- 🇨🇳
Research Site, Taipei, Taiwan
SHARE - Symbicort and Health Economics in a Real Life Evaluation
- Conditions
- Asthma
- First Posted Date
- 2005-12-01
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1970
- Registration Number
- NCT00259766
- Locations
- 🇸🇪
Reseearch Site, Perstorp, Sweden
🇸🇪Research Site, Örebro, Sweden
🇸🇪Research site, Ödeshög, Sweden
SYMPHONIE - A Comparison of Symbicort Single Inhaler and Conventional Best Practice for the Treatment of Persistent Asthma in Adolescents and Adults
- Conditions
- Asthma
- First Posted Date
- 2005-12-01
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT00259792
- Locations
- 🇫🇷
Research Sites, Creteil, France
🇫🇷Research Site, Marcq En Baroeul, France
🇫🇷Research site, Luneville, France
Comparison Between Symbicort® and Prednisolone in COPD
- Conditions
- Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2005-12-01
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT00259779
- Locations
- 🇸🇪
Research Site, Örebro, Sweden